/Regeneron%20Pharmaceuticals%20logo%20is%20seen%20on%20a%20screen%20and%20a%20hand%20holding%20pills_%20By%20Rafael%20Henrique.jpeg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company has a market capitalization of $82.3 billion and develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases, as well as cancer and more.
Companies with a market cap of $10 billion or more are typically referred to as “large-cap stocks.” REGN fits squarely into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the biotechnology industry.
